Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart

Histopathology

Volumn 67, Issue 5, 2015, Pages 625-635

  Chang, Chen ^a   Lin, Ching Hung ^b   Cheng, Ann Lii ^b   Medeiros, L Jeffrey ^c   Chang, Kung Chao ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antitumour immunity; Dendritic cells; Diffuse large B cell lymphoma; Primary central nervous system; Prognosis; T cells

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MEMORY T LYMPHOCYTE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; TUMOR BIOPSY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR ASSOCIATED LEUKOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84943348430     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12706     Document Type: Article

References (53)

1. Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J. Neurooncol. 2011; 101; 487-493.
2. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59; 240-244.
3. Ostrom QT, Gittleman H, Farah P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013; 15(Suppl. 2); ii1-ii56.
4. O'Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am. J. Hematol. 2013; 88; 997-1000.
5. Ferreri AJ. How I treat primary CNS lymphoma. Blood 2011; 118; 510-522.
6. Janeway CAJr, Travers P, Walport M, Shlomchik MJ (eds.) Immunobiology: the immune system in health and disease, 6th ed. New York: Garland Science Publishing, 2005; 630-642.
7. Rimsza LM, Leblanc ML, Unger JM et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112; 3425-3433.
8. Van Loo P, Tousseyn T, Vanhentenrijk V et al. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 2010; 95; 440-448.
9. McNutt M. Cancer immunotherapy. Science 2013; 342; 1417 (only 1 page).
10. Ansell SM, Hurvitz SA, Koenig PA et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 2009; 15; 6446-6453.
11. Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013; 31; 4199-4206.
12. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000; 18; 767-811.
13. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4 + T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J. Clin. Oncol. 2001; 19; 720-726.
14. Muraro S, Bondanza A, Bellone M, Greenberg PD, Bonini C. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4 + and CD8 + T-cell responses. Blood 2005; 105; 3596-3604.
15. Rimsza LM, Roberts RA, Miller TP et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103; 4251-4258.
16. Miller RA, Hart S, Samoszuk M et al. Shared idiotypes expressed by human B-cell lymphomas. N. Engl. J. Med. 1989; 321; 851-857.
17. Riemersma SA, Jordanova ES, Schop RF et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000; 96; 3569-3577.
18. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 2000; 18; 245-273.
19. Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin. Cancer Res. 2007; 13(22 Pt 1); 6666-6672.
20. Galand C, Donnou S, Molina TJ, Fridman WH, Fisson S, Sautes-Fridman C. Influence of tumor location on the composition of immune infiltrate and its impact on patient survival. Lessons from DCBCL and animal models. Front Immunol. 2012; 3; 98 (article 98; page 1-8).
21. Komohara Y, Horlad H, Ohnishi K et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J. Clin. Exp. Hematop. 2011; 51(2); 93-99.
22. Riemersma SA, Oudejans JJ, Vonk MJ et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J. Pathol. 2005; 206; 328-336.
23. Lin CH, Kuo KT, Chuang SS et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin. Cancer Res. 2006; 12; 1152-1156.
24. Swerdlow SH, Campo E, Harris NL et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008; 233-237.
25. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105; 1851-1861.
26. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53; 457-481.
28. Gehan EA. A generalized two-sample Wilcoxon test for doubly censored data. Biometrika 1965; 52; 650-653.
29. Cox DR. Regression models and life tables. J. R. Stat. Soc. Series B. Stat. Methodol. 1972; B34; 187-220.
30. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
31. Takahashi H, Tomita N, Yokoyama M et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 2012; 118; 4166-4172.
32. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993; 329; 987-994.
33. Lopez-Guillermo A, Colomo L, Jimenez M et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J. Clin. Oncol. 2005; 23; 2797-2804.
34. Muris JJ, Meijer CJ, Cillessen SA et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004; 18; 589-596.
35. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1 + cytotoxic T cells but not FOXP3 + regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br. J. Haematol. 2007; 137; 364-373.
36. Juszczynski P, Nowak J, Warzocha K. Host immune response in B-cell lymphomas: friend or foe? Arch. Immunol. Ther. Exp. (Warsz) 2008; 56; 245-255.
37. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 2000; 192; 755-760.
38. Ponzoni M, Berger F, Chassagne-Clement C et al. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br. J. Haematol. 2007; 138; 316-323.
39. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol. 2003; 21; 266-272.
40. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009; 15; 5494-5502.
41. Meyer PN, Fu K, Greiner TC et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011; 29; 200-207.
42. Giannini C, Dogan A, Salomao DR. CNS lymphoma: a practical diagnostic approach. J. Neuropathol. Exp. Neurol. 2014; 73; 478-494.
43. Song MK, Chung JS, Seol YM et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann. Oncol. 2010; 21; 140-144.
44. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93; 193-200.
45. Camilleri-Broet S, Criniere E, Broet P et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107; 190-196.
46. Bohlen H, Hopff T, Manzke O et al. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993; 82; 1803-1812.
47. Reusch U, Le Gall F, Hensel M et al. Effect of tetravalent bispecific CD19 × CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int. J. Cancer 2004; 112; 509-518.
48. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480; 480-489.
49. Colton CA. Immune heterogeneity in neuroinflammation: dendritic cells in the brain. J. Neuroimmune Pharmacol. 2013; 8; 145-162.
50. D'Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K. Brain dendritic cells: biology and pathology. Acta Neuropathol. 2012; 124; 599-614.
51. Melzer P, Savchenko V, McKanna JA. Microglia, astrocytes, and macrophages react differentially to central and peripheral lesions in the developing and mature rat whisker-to-barrel pathway: a study using immunohistochemistry for lipocortin1, phosphotyrosine, s100 beta, and mannose receptors. Exp. Neurol. 2001; 168; 63-77.
52. Muramatsu Y, Kurosaki R, Watanabe H et al. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice. Glia 2003; 42; 307-313.
53. Savchenko VL, McKanna JA, Nikonenko IR, Skibo GG. Microglia and astrocytes in the adult rat brain: comparative immunocytochemical analysis demonstrates the efficacy of lipocortin 1 immunoreactivity. Neuroscience 2000; 96; 195-203.